Congress Presentations

Stay informed about the latest scientific and medical research from Axsome.

Filter

Sort

Alzheimer’s Association International Conference (AAIC)

Philadelphia, PA | July 28 - August 01, 2024

AXS-05 | Alzheimer’s Disease Agitation

Featured Research Session #87680 Sunday, July 28, 2024: 4:15 PM – 5:45 PM EDT: Efficacy and Safety Of AXS-05 in Alzheimer’s Disease Agitation: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Study

View / Download

AXS-05 | Alzheimer’s Disease Agitation

Clinical Profile of AXS-05 in Treating Alzheimer’s Disease Agitation: Results from the Phase 2/3 Development Program

View / Download

AXS-05 | Alzheimer’s Disease Agitation

Dr. Jeffrey L. Cummings, MD, ScD describes the "Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program" AAIC 2024 poster

View

footer graphic

This site contains scientific information about investigational compounds and/or information about products and/or uses that have not been approved by the US Food and Drug Administration. The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.

AXSOME, AUVELITY, SUNOSI, SYMBRAVO and their logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2025 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY 10007